title: Circulating chemerin decreases in response to a combined strength and endurance training.
abstract: Chemerin is an adipokine that may mediate the link between obesity, inflammation, insulin resistance, type 2 diabetes mellitus, and cardiovascular disease. In this study, we examined the association between chemerin and various cardiometabolic risk factors in cross-sectional setting and tested the hypothesis that a 6-month combined exercise program decreases serum chemerin in overweight or obese, non-diabetic individuals. Serum chemerin concentration was measured in a cross-sectional analysis including 98 individuals with a wide range of age and body mass index (BMI). In addition, chemerin was measured in 79 sedentary, overweight or obese, non-diabetic individuals who completed a 6-month combined endurance and resistance exercise program (CEP, n = 51) or served as controls (C, n = 28). Chemerin was significantly associated with total cholesterol (p = 0.04), triglycerides (p < 0.001), fasting insulin (p < 0.001), homeostasis model assessment of insulin resistance (HOMA-IR, p < 0.001), systolic blood pressure (p = 0.04), highly sensitive C-reactive protein (p = 0.03), leucocytes count (p = 0.047), and leptin (p = 0.008) independently of age and BMI. In multiple regression analysis, chemerin was an independent determinant of HOMA-IR. As a result of the 6-month training program, serum chemerin decreased significantly in CEP group (-13.8 ± 13.2 ng/ml, p < 0.001). A significant association between the changes in chemerin and improved HOMA-IR were found even after adjustment for changes in waist circumference. Among non-diabetic individuals serum chemerin was associated with various cardiometabolic risk factors independently of BMI. In addition, the 6-month combined strength and endurance training program led to a significant reduction in circulating chemerin levels in overweight or obese individuals.
authors.affiliation: Medicobiological Unit, International Scientific Institute, National Sports Academy, Studentski Grad, 1700, Sofia, Bulgaria, tsvetan.stefanov@gmail.com.
authors.forename: Tsvetan
authors.initials: T
authors.lastname: Stefanov
authors.forename: Matthias
authors.initials: M
authors.lastname: Blüher
authors.forename: Anna
authors.initials: A
authors.lastname: Vekova
authors.forename: Iveta
authors.initials: I
authors.lastname: Bonova
authors.forename: Stanislav
authors.initials: S
authors.lastname: Tzvetkov
authors.forename: Dimo
authors.initials: D
authors.lastname: Kurktschiev
authors.forename: Theodora
authors.initials: T
authors.lastname: Temelkova-Kurktschiev
mesh_terms: D000328:Adult; D000886:Anthropometry; D015992:Body Mass Index; D002318:Cardiovascular Diseases / Q000097:blood / Q000628:therapy; D018925:Chemokines / Q000097:blood*; D003430:Cross-Sectional Studies; D005081:Exercise Therapy / Q000379:methods*; D005260:Female; D006801:Humans; D007333:Insulin Resistance / Q000502:physiology; D036341:Intercellular Signaling Peptides and Proteins; D008297:Male; D008875:Middle Aged; D009765:Obesity / Q000097:blood / Q000628:therapy; D050177:Overweight / Q000097:blood* / Q000628:therapy; D010807:Physical Endurance / Q000502:physiology; D055070:Resistance Training / Q000379:methods; D012307:Risk Factors; D016896:Treatment Outcome
chemical_list: D018925:Chemokines; D036341:Intercellular Signaling Peptides and Proteins; C478630:RARRES2 protein, human